Pindobind

Pindobind
Names
	IUPAC name 2-Bromo-N-[4-(2-{[2-hydroxy-3-(1H-indol-4-yloxy)propyl]amino}-2-propanyl)-1-methylcyclohexyl]acetamide
Identifiers
CAS Number	106469-52-7 ;
3D model (Jmol)	Interactive image;
ChemSpider	4661;
PubChem CID	4827;
	InChI InChI=1S/C23H34BrN3O3/c1-22(2,16-7-10-23(3,11-8-16)27-21(29)13-24)26-14-17(28)15-30-20-6-4-5-19-18(20)9-12-25-19/h4-6,9,12,16-17,25-26,28H,7-8,10-11,13-15H2,1-3H3,(H,27,29) Key: XSAGAZCYTLNCEN-UHFFFAOYSA-N ; InChI=1/C23H34BrN3O3/c1-22(2,16-7-10-23(3,11-8-16)27-21(29)13-24)26-14-17(28)15-30-20-6-4-5-19-18(20)9-12-25-19/h4-6,9,12,16-17,25-26,28H,7-8,10-11,13-15H2,1-3H3,(H,27,29) Key: XSAGAZCYTLNCEN-UHFFFAOYAL ;
	SMILES BrCC(=O)NC1(C)CCC(CC1)C(NCC(O)COc2cccc3c2ccn3)(C)C ;
Properties
Chemical formula	C23H34BrN3O3
Molar mass	480.45 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

Pindobind is a compound developed by researchers associated with Stanford University,^[1] identified as a central nervous system depressant,^[2] which generated a response in animals reducing offensive actions such as chasing, while also notably reducing tendencies of the test animal to evade when stimulated to do so.^[2] It acts as an irreversible beta blocker and irreversible 5-HT_1A receptor antagonist.

References[edit]

^ Peroutka, Stephen J.; Pitha, Josef (Jul 20, 1993), Method for relieving anxiety using 5-hydroxytryptamine-1a-receptor-binding compounds, retrieved 2016-06-04
^ ^a ^b Bell, R; Hobson, H (1993). "Effects of pindobind 5-hydroxytryptamine1A (5-HT1A), a novel and potent 5-HT1A antagonist, on social and agonistic behaviour in male albino mice". Pharmacology, Biochemistry, and Behavior. 46 (1): 67–72. doi:10.1016/0091-3057(93)90318-N. PMID 8255924.

v t e Beta blockers (C07)

β, non-selective	Alprenolol Bopindolol Bupranolol Carteolol Cloranolol Mepindolol Nadolol Oxprenolol Penbutolol Pindolol/Iodopindolol Propranolol Sotalol Tertatolol Timolol

β₁-selective	Acebutolol Atenolol Betaxolol Bevantolol Bisoprolol Celiprolol Epanolol Esmolol Landiolol Metoprolol Nebivolol Practolol S-Atenolol Talinolol

β₂-selective	Butaxamine

α₁- + β-selective	Arotinolol Carvedilol Labetalol

^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III